Pneumococcal Vaccine Market Report 2026

Pneumococcal Vaccine Market Overview

• Pneumococcal Vaccine market size has reached to $9.4 billion in 2025 • Expected to grow to $12.76 billion in 2030 at a compound annual growth rate (CAGR) of 6.5% • Growth Driver: Rising Prevalence Of Pneumococcal Contamination Drives Growth In Pneumococcal Vaccine Market • Market Trend: Breakthrough In Vaccine For Enhanced Adult Protection • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Pneumococcal Vaccine Market?

The pneumococcal vaccine refers to a vaccination that offers defense against potentially fatal and severe pneumococcal infections caused by streptococcus pneumoniae bacteria, such as pneumonia, meningitis, and sepsis. It is highly efficient in protecting infants from one of the most common causes of meningitis and other illnesses, such as acute ear infections. The main pneumococcal vaccines are Prevnar 13, synflorix, pneumovax23, and others. Prevnar 13 refers to a pneumococcal conjugate vaccine containing 13 distinct strains of Streptococcus pneumoniae and it is used in children and tested on immunocompromised patients to prevent pneumococcal disease. The various routes of administration include intravenous, intramuscular, and subcutaneous and are distributed via pharmacies, community clinics, public health agencies, and other distribution channels to end users such as pediatrics and adults.

What Is The Pneumococcal Vaccine Market Growth Forecast?

The pneumococcal vaccine market size is expected to see strong growth in the next few years. It will grow to $12.76 billion in 2030 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to launch of next-generation pcv vaccines, expanding adult vaccination recommendations, growth in healthcare access in emerging economies, increasing antimicrobial resistance concerns, government funding for preventive immunization. Major trends in the forecast period include expansion of conjugate vaccines for broader serotype coverage, increased focus on pediatric and geriatric immunization programs, rising adoption of combination and booster vaccination strategies, strengthening public–private partnerships for immunization coverage, growth in preventive healthcare and national immunization schedules.

Global Pneumococcal Vaccine Market Segmentation

1) By Product Type: Prevnar 13, Synflorix, Pneumovax23, Other Products 2) By Route of Administration: Intravenous, Intramuscular, Subcutaneous 3) By Distribution Channel: Pharmacies, Community Clinics, Public Health Agencies, Other Distribution Channels 4) By End User: Pediatrics, Adults Subsegments: 1) By Prevnar 13: Pediatric Formulation, Adult Formulation 2) By Synflorix: Pediatric Formulation, Adult Formulation 3) By Pneumovax23: Single-Dose Vials, Pre-Filled Syringes 4) By Other Products: PCV15 (Vaxneuvance), PCV20 (Prevnar 20), Other Regional Pneumococcal Vaccines

What Is The Driver Of The Pneumococcal Vaccine Market?

The increasing prevalence of pneumococcal contamination is expected to propel the growth of the pneumococcal vaccine market going forward. Pneumococcal contamination refers to any infection caused by bacteria called Streptococcus pneumoniae or pneumococcus, such as pneumonia, bloodstream infections, ear infections, and sinus infections. The pneumococcal vaccine stimulates the body to produce antibodies against pneumococcal bacteria to reduce or destroy disease-carrying bacteria and toxins to protect children, the elderly, and those with weakened immune systems from many types of pneumococcal infections. For instance, in July 2025, according to the Immunisation Coalition, a Australia-based, independent not-for-profit charity, cases of invasive pneumococcal disease (IPD) have steadily increased each year, growing from 1,869 in 2022 to 2,265 in 2023, and reaching 2,379 in 2024. Therefore, the increasing prevalence of pneumococcal contamination is driving the growth of the pneumococcal vaccine industry.

Key Players In The Global Pneumococcal Vaccine Market

Major companies operating in the pneumococcal vaccine market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline plc, CSL Limited, Anhui Zhifei Longcom Biopharmaceutical Co. Ltd, Serum Institute of India Private Limited, Walvax Biotechnology Co. Ltd, Biological E Limited, Hualan Biological Engineering Inc., Beijing Minhai Biotechnology Limited Company, NPO Petrovax Pharm LLC, Vaxcyte Inc., Panacea Biotec Ltd, PnuVax Incorporated, SK Bioscience Co Ltd, Bharat Biotech International Ltd, Medicago Inc., Emergent BioSolutions Inc., Valneva SE

Global Pneumococcal Vaccine Market Trends and Insights

Major companies operating in the pneumococcal vaccine market are innovating new products to increase their profitability in the market. For instance, in July 2023, Merck & Co Inc., a US-based pharmaceuticals company launched the V116 vaccine. V116 is intended to target the eight distinct serotypes of Streptococcus pneumoniae that are primarily responsible for adult pneumococcal disease. Compared to other pneumococcal vaccines, V116 has shown better immunogenicity for a variety of serotypes in adult populations, and it has also produced positive immune responses in both vaccine-naïve and previously vaccinated individuals. The U.S. Food and Drug Administration (FDA) has designated V116 as a breakthrough therapy, and it is currently in Phase 3 development.

What Are Latest Mergers And Acquisitions In The Pneumococcal Vaccine Market?

In December 2024, Sanofi SA, a France-based pharmaceutical company, expanded its collaboration with SK Bioscience Co. Ltd. to advance the development of its licensed pneumococcal conjugate vaccine. Through this collaboration expansion, Sanofi aims to accelerate late-stage development and strengthen its pneumococcal vaccine portfolio by leveraging SK Bioscience’s advanced vaccine manufacturing and development capabilities. SK Bioscience Co. Ltd. is a South Korea-based biotechnology company specializing in pneumococcal vaccine R&D and biomanufacturing.

Regional Insights

North America was the largest region in the pneumococcal vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Pneumococcal Vaccine Market?

The pneumococcal vaccine market consists of sales of vaxneuvance, prevnar 20, pneumococcal conjugate vaccines (PCV)10, and pneumococcal conjugate vaccines (PCV)7. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Pneumococcal Vaccine Market Report 2026?

The pneumococcal vaccine market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the pneumococcal vaccine industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.